Blueprint Medicines
(NASDAQ) BPMC
This security has been delisted. This page is retained for historical reference.
BPMC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowBPMC Financials
Key Financial Metrics (TTM)
Gross Margin
96.04%
Operating Margin
-41.67%
Net Income Margin
-13.19%
Return on Equity
-31.26%
Return on Capital
-27.62%
Return on Assets
-5.69%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$538.73M
Operating Income
-$174.31M
EBITDA
-$95.68M
Operating Cash Flow
-$145.55M
Capital Expenditure
-$5.36M
Free Cash Flow
-$150.91M
Cash & ST Invst.
$576.24M
Total Debt
$122.75M
Blueprint Medicines Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$149.41M
+55.5%
Gross Profit
$146.61M
+66.4%
Gross Margin
98.12%
N/A
Market Cap
N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
N/A
N/A
Employees
682
N/A
Net Income
$496.00K
-99.4%
EBITDA
-$5.72M
-105.2%
Quarterly Fundamentals
Total Cash
$576.24M
-11.1%
Total Debt
$122.75M
-79.5%
Accounts Receivable
$79.80M
+32.9%
Inventory
$12.95M
-58.1%
Long Term Debt
$130.43M
-74.5%
Short Term Debt
$71.27M
+68.0%
Return on Assets
-5.69%
N/A
Return on Invested Capital
-23.07%
N/A
Free Cash Flow
-$56.31M
+45.1%
Operating Cash Flow
-$54.48M
+46.3%